Barclays
IRON icon

Barclays’s Disc Medicine IRON Stock Holding History

Barclays’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
18,710
-14,557
-44% -$1M ﹤0.01% 2603
2026
Q1 		$2.13M Sell
33,267
-66,345
-67% -$4.6M ﹤0.01% 2322
2025
Q4 		$7.91M Sell
99,612
-7,591
-7% -$641K ﹤0.01% 1873
2025
Q3 		$7.08M Buy
107,203
+20,645
+24% +$1.23M ﹤0.01% 1946
2025
Q2 		$4.58M Buy
86,558
+40,850
+89% +$1.92M ﹤0.01% 2210
2025
Q1 		$2.27M Buy
45,708
+5,644
+14% +$314K ﹤0.01% 2539
2024
Q4 		$2.54M Sell
40,064
-81
-0.2% -$4.68K ﹤0.01% 2711
2024
Q3 		$1.97M Buy
40,145
+22,202
+124% +$1.04M ﹤0.01% 2853
2024
Q2 		$809K Buy
17,943
+3,520
+24% +$120K ﹤0.01% 2732
2024
Q1 		$898K Sell
14,423
-14,041
-49% -$910K ﹤0.01% 3205
2023
Q4 		$1.64M Sell
28,464
-3,097
-10% -$159K ﹤0.01% 3070
2023
Q3 		$1.48M Buy
31,561
+30,008
+1,932% +$1.5M ﹤0.01% 2073
2023
Q2 		$69K Sell
1,553
-4,066
-72% -$144K ﹤0.01% 3708
2023
Q1 		$119K Buy
5,619
+5,419
+2,710% +$121K ﹤0.01% 4084
2022
Q4 		$3.98K Buy
+200
New +$9.96K ﹤0.01% 5030
2022
Q2 		– Sell
-119
Closed -$5K – 5146
2022
Q1 		$5K Buy
+119
New +$6.24K ﹤0.01% 4696

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's IRON Position: Q2 2026 in Review

Barclays reduced its Disc Medicine (IRON) stake by 44% in Q2 2026, selling an estimated $1M and leaving 18,710 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2603.

Barclays first reported a position in IRON in Q1 2022 and has held it in 16 quarters since. The position peaked at $7.91M in Q4 2025. 215 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Barclays held 18,710 shares of Disc Medicine worth $1.37M as of Q2 2026.
  • Barclays sold 14,557 Disc Medicine shares in Q2 2026, an estimated $1M.
  • Disc Medicine made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2603 holding.
  • Barclays first reported a position in Disc Medicine in Q1 2022 and has held it in 16 quarters since.
  • Barclays's Disc Medicine position peaked at $7.91M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.